CNBC July 26, 2021
Key Points
– BioNTech announced Monday it plans to develop a highly effective mRNA-based vaccine to prevent malaria.
– It said it is aiming to begin clinical trials testing the shot by the end of 2022.
– The company also developed the United States’ first authorized Covid-19 vaccine with U.S. drugmaker Pfizer.
German drugmaker BioNTech announced Monday it plans to develop an mRNA-based vaccine to prevent malaria, a life-threatening disease that impacts millions of people worldwide each year.
The company, which developed the United States’ first authorized Covid-19 vaccine with U.S. drugmaker Pfizer, said it is aiming to begin clinical trials testing the shot by the end of 2022.
The World Health Organization, European Commission and other organizations have been...
Today's Sponsors
Today's Sponsor